Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA, UK.
National Institute for Health Research - Leeds Biomedical Research Centre (NIHR-LBRC), Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Arthritis Res Ther. 2017 Dec 22;19(1):288. doi: 10.1186/s13075-017-1492-9.
Individuals at risk of rheumatoid arthritis (RA) demonstrate systemic autoimmunity in the form of anti-citrullinated peptide antibodies (ACPA). MicroRNAs (miRNAs) are implicated in established RA. This study aimed to (1) compare miRNA expression between healthy individuals and those at risk of and those that develop RA, (2) evaluate the change in expression of miRNA from "at-risk" to early RA and (3) explore whether these miRNAs could inform a signature predictive of progression from "at-risk" to RA.
We performed global profiling of 754 miRNAs per patient on a matched serum sample cohort of 12 anti-cyclic citrullinated peptide (CCP) + "at-risk" individuals that progressed to RA. Each individual had a serum sample from baseline and at time of detection of synovitis, forming the matched element. Healthy controls were also studied. miRNAs with a fold difference/fold change of four in expression level met our primary criterion for selection as candidate miRNAs. Validation of the miRNAs of interest was conducted using custom miRNA array cards on matched samples (baseline and follow up) in 24 CCP+ individuals; 12 RA progressors and 12 RA non-progressors.
We report on the first study to use matched serum samples and a comprehensive miRNA array approach to identify in particular, three miRNAs (miR-22, miR-486-3p, and miR-382) associated with progression from systemic autoimmunity to RA inflammation. MiR-22 demonstrated significant fold difference between progressors and non-progressors indicating a potential biomarker role for at-risk individuals.
This first study using a cohort with matched serum samples provides important mechanistic insights in the transition from systemic autoimmunity to inflammatory disease for future investigation, and with further evaluation, might also serve as a predictive biomarker.
类风湿关节炎(RA)风险个体表现出以抗瓜氨酸化肽抗体(ACPA)为形式的系统性自身免疫。microRNAs(miRNAs)与已确立的 RA 有关。本研究旨在:(1)比较健康个体与 RA 风险个体和已发展为 RA 的个体之间的 miRNA 表达;(2)评估 miRNA 从“风险”到早期 RA 的表达变化;(3)探讨这些 miRNA 是否可以提供从“风险”到 RA 进展的预测特征。
我们对 12 名抗环瓜氨酸肽(CCP)抗体阳性的“风险”个体进展为 RA 后的匹配血清样本队列进行了每位患者 754 个 miRNA 的全谱分析。每位个体均有基线和滑膜炎症检测时的血清样本,形成匹配元素。还对健康对照进行了研究。表达水平的倍数差异/倍数变化达到四个的 miRNA 符合我们作为候选 miRNA 选择的主要标准。在 24 名 CCP 阳性个体的匹配样本(基线和随访)上使用定制 miRNA 阵列卡对感兴趣的 miRNA 进行了验证;其中 12 名 RA 进展者和 12 名 RA 非进展者。
我们报告了第一项使用匹配血清样本和综合 miRNA 阵列方法的研究,该研究特别确定了三种与系统性自身免疫向 RA 炎症进展相关的 miRNA(miR-22、miR-486-3p 和 miR-382)。miR-22 在进展者和非进展者之间表现出显著的倍数差异,表明其在风险个体中具有潜在的生物标志物作用。
这项使用具有匹配血清样本的队列的首次研究提供了从系统性自身免疫到炎症性疾病的转变的重要机制见解,为未来的研究提供了重要的机制见解,并且通过进一步评估,也可能作为预测生物标志物。